Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: Short-term and long-term results

Cardiovascular Drugs and Therapy

Volumn 13, Issue 5, 1999, Pages 423-428

  Di Pasquale, Pietro ^a   Lo Verso, Pietro ^a   Bucca, Vincenzo ^a   Cannizzaro, Sergio ^a   Scalzo, Sebastiano ^a   Maringhini, Giorgio ^a   Rizzo, Rosa ^a   Paterna, Salvatore ^b  

^a Ospedale GF Ingrassia   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Acute myocardial infarction; Reperfusion; Thrombolysis; Trimetazidine

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RETEPLASE; TRIMETAZIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; HEART VENTRICLE ARRHYTHMIA; HEART VOLUME; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; SYSTOLE;

AGED; ANALYSIS OF VARIANCE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CREATINE KINASE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; THROMBOLYTIC THERAPY; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 0032858431     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007804007115     Document Type: Article

References (38)

1. Ambrosio G, Welsfeldt ML, Jacobus WE, Flaherty JT. Evidence for a reversible oxygen radical-mediated component of reperfusion injury: Reduction by recombinant superoxide dismutase administered at the time of reflow. Circulation 1987;75:282-291.
2. Burton KP, Evidence of direct toxic effects of free radicals on the myocardium. Free Rad Biol Med 1988;4:15-24.
3. Jennings RB, Reimer KA. Factors involved in salvaging ischemic myocardium. Effects of reperfusion of arterial blood. Circulation 1983;68(Suppl):I-25-I-36.
4. Becker LC, Ambrosio G. Myocardial consequences of reperfusion. Prog Cardiovasc Dis 1987;30:23-44.
5. Harpey C, Clauser P, Labrid C, Freyria H, Poirier JP. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Drug Rev 1988;6:292-312.
6. Belcher P, Drake-Holland AJ, Hynd JW, Noble MIM. Trimetazidine reduces myocardial infarct size, relative area at risk, after temporary artery occlusion in the rabbit. Br J Pharmacol 1992;107:265P.
7. Drake-Holland AJ, Belcher PR, Hynd JW, Noble IM. Infarct size in rabbits: A modified illustrated by the effects of propanolol and trimetazidine. Basic Res Cardiol 1993; 88:250-258.
8. Takenada F, Sakaniski M, Watanabe A. Effects of trimetazidine in the coronary circulation and myocardial metabolism in the dog. Pharmacometrics 1976;11:429-435.
9. Fabiani JN, Ponzio O, Emerit I, Massonet-Castel S, Paris M, Chevalier P, Jebara B, Carpentier A. Cardioprotective effects of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg 1992;33:486-490.
10. Kober G, Buck T, Severt H, Vallbracht C. Myocardial protection during percutaneous transluminal coronary angioplasty: Effects of trimetazidine. Eur Heart J 1992;13: 1109-1115.
11. Di Pasquale P, Bucca V, Giuliano P, Maringhini G, Scalzo S, Paterna S. Advantages of immediate two-dimensional echo-cardiography in patients with acute cardiac ischemic events. Int J Cardiol 1995;51:85-91.
12. Honore E, Adamantidis MM, Challice CE, Dupuis BA. Cardioprotection by calcium antagonist, piridoxilate and trimetazidme. RCS Med Sci 1986;14:338-339.
13. Lavanchy N, Martin J, Rossi A. Anti-ischemic effects of trimetazidine: P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987;286:97-110.
14. Bricaud H, Brottier I, Barat JH, Combe C, Broussens B, Bonnet J. Cardioprotective effect of trimetazidine in severe ischemic cardiomyopathy. Cardiovasc Drug Ther 1990;4: 861-865.
15. Fantini E, Demaison L, Sentex E, Grynberg A, Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994;26:949-958.
16. Cruz C, Zaoui A, Ayoub S, Harpey C, Goupil P, Younes A. Alterations des myocytes isole' des ventricules de coeur de rat adulte: Protection par la Trimetazidine Concours Medicale. 1987;36(Suppl 34):70-75.
17. Nagata M, Imamura I, Fugono R, Sugimoto J. The actions of trimetazidine on isolated guinea-pig atria. Jpn J Pharmacol 1971;21:337-343.
18. -+ regulation by trimetazidine during cardiac cell necrosis. Cardiovasc Drug Ther 1988;1:677-686.
19. Mardonneau-Parini I, Harpey C. Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985;20:148-151.
20. Clauser P, Harpey C. Anti-oxidant properties of an anti-ischemic agent. Trimetazidine. In: Emeril J, Packer L, Auclair C, eds. Antioxidants in Therapy and Preventive Medicine, New York; Plenum Press, 1990: 247-250.
21. Rahman F, Toshiba Y, Kohno H, Kinoshita K, Tokunaga K. The protective effects of trimetazidine on normothermic ischemic myocardium in rats. Jpn J Surg 1989;19:346-350.
22. Guamieri C, Muscari C. Effect of trimetazidine on mithocondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium. Pharmacology 1993;46:324-331.
23. Guamieri C. How can cardiac mitochondrial metabolism be manipulated? Dialogues Cardiovasc Med 1996;1:89-92.
24. Kay L, Finelli C, Aussedat J, Guarnieri C, Rossi A. Improvement of long-term preservation of the isolated rat heart by trimetazidine: Effects on the energy state and mitochondrial function. Am J Cardiol 1995;76:45B-49B.
25. de Leiris J, Bouder F. Rationale for trimetazidine administration in myocardial ischemia reperfusion syndrome. Eur Heart J 1993;14(Suppl G):34-40.
26. Manning AS, Hearse DJ. Reperfusion-induced arrhythmias: Mechanisms and prevention. J Mol Cell Cardiol 1984;16: 497-518.
27. Maupoil V, Rochette L, Tabard A, Clauser P, Arpey C. Direct measurements of the free radical generation in isolated rat heart by electron paramagnetic resonance spectroscopy: Effect of Trimetazidine, In: Emerit I, Packer L, Auclair C, eds. Antioxidants in Therapy and Preventive Medicine. Adv Esp Ed Biol 1990;264:373-376.
28. Charlene V, Boucher F, Closer P, et al. Effect of a 5 day trimetazidine pretreatment in a model of ischemic and reperfused isolated rat heart: spin trapping experiments. In: Emerit I, Pecker L, Auclair C, eds. Antioxidants in Therapy and Preventive Medicine. Adv Exp Med Biol 1990;264: 377-382.
29. Williams FM, Tanda K, Kas M, Williams TJ. Inhibition of neutrophil accumulation into ischemic reperfused myocardium in the rabbit by trimetazidine. J Mol Cell Cardiol 1992;24(Suppl 1):S90.
30. Camilleri JP, Joseph D. Effects de la trimetazidine sur I'in-farctus experimental du rat reperfusé. Arch Mal Coeur Vaisseaux 1988;81:371-376.
31. Sellier P, Audoin P, Rayen B, Corona P, Duong TC, Ourbak P. Acute effects of trimetazidine evaluated by exercise testing. Eur Clin Pharmacol 1987;33:205-207.
32. Dalla Volta S, Maraglino G, Della Valentina P, Desideri A. Comparison of trimetizidine with nifedipine in effort angina: a double blind cross-over study. Cardiovasc Drug Ther 1990;4:853-860.
33. Lu C, Dabrowski P, Fragasso G, Chierca S. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease: A randomized double-blind placebo-controlled, crossover study (Abstract). Circulation 1997;96(Suppl):I-91.
34. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine a new concept in the treatment of angina. Comparison with propanolol in patients with stable angina. Br J Clin Pharmacol 1994;37:279-288.
35. Brottier L, Barat I, Combe C, Boussens B, Bonnet J, Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 1990;11:207-212.
36. EMIP-FR Pilot Study Group. Free radicals reperfusion and myocardial infarction therapy: European Myocardial Infarction Project-Free radical Pilot study EMIP-FR Pilot Study Group. Eur Heart J 1993;14(Suppl G):48-51.
37. Drobrusky G, Deroux A, Schutz D. Traitement de I'angor par Vastarel 20 mg en pratique medicale quotidienne. Vie Medicale 1985;9:441-448.
38. Guillaumet D, Scutz D. Vastarel 20 mg: efficacité et securité d'emploi en cardiologie chez 906 patients insuffisant coronariens. Tempo Med 1982;110:74-78.